Goldman Sachs maintains its Neutral rating on Clorox Co (NYSE: CLX, despite its fourth-quarter results missing estimates as higher costs offset volume gains.
The results showed that the company's positive gross margin streak came to an end amid fading input costs benefit and increasing price investments due to stiff competition. But, volume gains displayed "surprising" resiliency.
"While the optics of the strong 4Q volume growth (nearly +6 percent) raises questions of sustainability, we believe the growth is in part sustainable and view the low end of its 2–4 percent organic sales target next year as achievable on volume gains alone," analyst Jason English wrote in a note.
"The high-end, however, strikes us as likely out of reach, especially given onerous comparisons this year," English continued.
In addition, the analyst raised his FY17 estimates to reflect the new accounting changes. English now expects FY17 EPS of $5.45 (up from $5.21) on revenue of $5.96 billion (up from $5.97 billion).
Further, English cut the price target on the stock by $1 to $130 to reflect slowing fundamentals and accounting-adjustment inflation of EPS.
Shares of Clorox closed Wednesday's regular trading session at $131.59, and were up 1.21 percent to $133.18 at time of writing Thursday.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
